Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study

摘要: Background: For HER2 positive metastatic breast cancer (MBC), continuing anti-HER2 therapy beyond progression is associated with improved outcome. However retreatment trastuzumab after lapatinib controversial. We retrospectively analyzed the efficacy of trastuzumab-based chemotherapy in HER2+ patients whose disease progressed lapatinib. Materials and Methods: Between October 2010 May 2013, 54 were retreated chemotherapy. Efficacy toxicity results evaluated retrospectively. Results: The median age was 46 (range 27-67). Fourteen (26%) had metastases at time diagnosis. All received an adjuvant or setting, while 16 (30%) two lines trastuzumab. plus capecitabine. line for setting 2 1-7). Cranial identified 27 (50%) patients. 53 following one patient monotherapy. Combination consisted navelbin (n=33), taxane (n=10), gemcitabine (n=2), platinum (n=2) (n=6). treatment cycle 5 1-44). Among 49 assessed response (4%) showed CR, 12 (25%) PR, 11 (22%) SD 24 (49%) progression. Asymptomatic cardiotoxicity reported At a follow-up 9 months (1-39), progression-free survival (95% CI 4.1-5.9) overall 10 6.9-13.0). PFS OS not affected by absence/presence cranial metastases. Conclusions: Retreatment heavily treated MBC